Compare Merck & Co., Inc. (MRK) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Koninklijke Philips NV — how do they compare? Merck & Co., Inc. trades at $142.33 (market cap $351.28B), while Koninklijke Philips NV trades at $24.51 (market cap $23.52B). The key difference: Merck & Co., Inc. is far larger — about 14.9× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (4.17%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Koninklijke Philips NV for 84 Days on average.
| MRK | PHG | |
|---|---|---|
Market Cap | $351.28B | $23.52B |
Volume | 7,969,665 | 1,635,069 |
Sector | Health | Health |
52-Week High | $156.43 | $32.91 |
52-Week Low | $82.49 | $23.81 |
Typical Hold Time | 98 Days | 84 Days |
Enterprise Value | $398.04B | $29.87B |
Dividend Yield | 2.39% | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
PHG trades at $24.09, down 0.25% on the day, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong operational cash flow of $1.17B. Recent news highlights product innovations including new CT systems and AI healthcare tools, while institutional investors like Bank of America and Arrowstreet Capital have increased positions.
PHG presents a mixed outlook with solid profitability recovery but technical weakness. The stock offers value at reasonable valuations (P/E 18.84, P/S 1.18) and analyst consensus leans Hold (63.64%). Key risks include cybersecurity threats (Reuters, 2026-08-13) and debt levels, while opportunities lie in healthcare technology expansion and Exor's potential increased stake to 22% (Reuters, 2026-08-11).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
